1073P - Consolidation treatment with y90-ibritumomab tiuxetan after r-chop induction in high-risk patients with follicular lymphoma (FL) (GOTEL-FL1LC): a mu...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer Agents
Biological Therapy
Presenter Mariano Provencio Pulla
Authors M. Provencio Pulla1, M.A. Cruz Mora2, J. Gomez Codina3, C. Quero4, M. Llanos5, F.R. Garcia Arroyo6, L. De La Cruz7, J. Guma8, J.R. Delgado9, A. Rueda10
  • 1Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 2Medical Oncology, Hospital Virgen de la Salud, Toledo/ES
  • 3Medical Oncology, Hospital Universitari i Polit, ES-46026 - Valencia/ES
  • 4Radiotherapy, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 5Medical Oncology, Hospital Universitario de Canarias, Tenerife/ES
  • 6Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra/ES
  • 7Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla/ES
  • 8Oncology Service, Hospital Universitario San Juan de Reus, Reus/ES
  • 9Medical Oncology, Hospital Universitario Virgen de las Nieves, Granada/ES
  • 10Medical Oncology, Hospital Costa del Sol, Marbella/ES


Relapse is the main cause of therapeutic failure in FL, which makes it necessary to investigate strategies that aim to eradicate minimal residual disease. This is why we set out to evaluate the role of consolidation with Y90-Ibritumomab Tiuxetan (RIT) in high-risk FL patients. As we possessed data making us suspect that prior treatment with Rituximab could reduce the efficacy of RIT, we designed a study with RIT after 4 cycles of CHOP-R and 2 CHOP, but without R.

Material and Patients

Between April 2008 and April 2010, 30 patients were included in this trial: 17 male (56.7%) and 13 female (43.3%). Their median age was 54.8 (range, 34-76). 20 (69%) patients had ECOG 0. There were no delays or reductions in RIT doses.


The objective rate of clinical response was 92.1% (CR + CRi + PR), [CI 95%: 83-100%]. Of the 18 patients who presented with partial remission to the induction treatment, 11 (61.1%) had complete CR or remission after the consolidation treatment. There was only one exitus, due to H1N1 viral pneumonia. The most important G 3/4 toxicity was hematological, with 46% thrombopenia and 56% neutropenia. None of the patients in the trial died because of Lymphoma. With median follow-up of 26 months (12-37), the means for disease-free survival or overall survival were not reached.


The induction procedure with 4 CHOP-R + 2 CHOP prior to consolidation with RIT gives good response rates and RIT improves CR. This combination is safe and shows a high activity in both, induction and consolidation procedures.


All authors have declared no conflicts of interest.